全文获取类型
收费全文 | 67784篇 |
免费 | 6433篇 |
国内免费 | 2876篇 |
专业分类
耳鼻咽喉 | 743篇 |
儿科学 | 1246篇 |
妇产科学 | 1117篇 |
基础医学 | 7306篇 |
口腔科学 | 1248篇 |
临床医学 | 7835篇 |
内科学 | 10457篇 |
皮肤病学 | 1306篇 |
神经病学 | 4162篇 |
特种医学 | 2070篇 |
外国民族医学 | 15篇 |
外科学 | 7414篇 |
综合类 | 9718篇 |
现状与发展 | 20篇 |
一般理论 | 44篇 |
预防医学 | 5426篇 |
眼科学 | 2128篇 |
药学 | 6574篇 |
73篇 | |
中国医学 | 3518篇 |
肿瘤学 | 4673篇 |
出版年
2024年 | 194篇 |
2023年 | 862篇 |
2022年 | 2272篇 |
2021年 | 3170篇 |
2020年 | 2481篇 |
2019年 | 2123篇 |
2018年 | 2389篇 |
2017年 | 2250篇 |
2016年 | 2118篇 |
2015年 | 2830篇 |
2014年 | 3446篇 |
2013年 | 3561篇 |
2012年 | 5400篇 |
2011年 | 5522篇 |
2010年 | 3640篇 |
2009年 | 3076篇 |
2008年 | 4092篇 |
2007年 | 3931篇 |
2006年 | 3643篇 |
2005年 | 3476篇 |
2004年 | 2540篇 |
2003年 | 2272篇 |
2002年 | 1930篇 |
2001年 | 1169篇 |
2000年 | 1130篇 |
1999年 | 990篇 |
1998年 | 681篇 |
1997年 | 548篇 |
1996年 | 410篇 |
1995年 | 411篇 |
1994年 | 359篇 |
1993年 | 254篇 |
1992年 | 402篇 |
1991年 | 386篇 |
1990年 | 354篇 |
1989年 | 308篇 |
1988年 | 269篇 |
1987年 | 249篇 |
1986年 | 258篇 |
1985年 | 200篇 |
1984年 | 164篇 |
1983年 | 131篇 |
1982年 | 118篇 |
1981年 | 99篇 |
1980年 | 81篇 |
1979年 | 96篇 |
1978年 | 83篇 |
1977年 | 83篇 |
1974年 | 83篇 |
1972年 | 75篇 |
排序方式: 共有10000条查询结果,搜索用时 62 毫秒
41.
黄芪始载于《神农本草经》,有补气升阳、益卫固表,利水消肿,托毒生肌之效。被誉为补气健脾之要药,临床上常用于气虚乏力、脾虚泄泻等疾病,已为医者所熟知。近年来,研究学者围绕其补气、健脾、利水功效机制已有较全面的认识。然陶弘景在《本草经集注》首载黄芪"逐五脏间恶血",表明本品兼有活血作用。目前,对于本品活血作用机制阐释,中医常基于"补气活血""气行血行"理论进行论证,但并不等同于本品无活血作用。通过梳理历代本草文献中对黄芪的记载,发现其活血作用应用广泛。综合传统方剂与现代方剂中有关其活血作用的应用,本品在方中行活血通络、活血利水、活血扶正作用,尤能体现其活血作用。且现代药理学研究在有关瘀血病理指标的分子机制中,黄芪有很好的调控作用,表明黄芪有活血作用,但未深入探究,存在研究价值。该文从历代文献对黄芪活血功效的论述、黄芪活血作用的临床应用及现代药理学研究深入探讨其活血作用机制,以期扩展黄芪的临床应用范围,为临床治疗提供理论指导。 相似文献
42.
44.
Han Wang Hui Ding Bo-wen Ouyang Zhenduo Yang Tan Zhong Hongming Fan Xingwu Zhong 《Eye (London, England)》2020,34(12):2328
ObjectivesTo investigate the effect of corneal stromal pocket irrigation after small-incision lenticule extraction (SMILE) on visual acuity, intraocular pressure (IOP), corneal parameters and complications after surgery.MethodsA total of 242 eyes of 121 patients undergoing SMILE were enrolled in this prospective controlled study, and it was designed for one eye to randomly undergo SMILE with balanced salt solution irrigation of the corneal stromal pocket, while the other eye was not. The uncorrected distance visual acuity (UDVA) and slit lamp examination were recorded at 1 hour, 1 day, 1 week, and 1 month. Postoperative corneal density, corneal biomechanical, corneal endothelial cell number, and anterior OCT images were compared at 1 day, 1 week, and 1 month.ResultsCompared with the nonirrigation group, the irrigation group showed significantly higher UDVA at 1 day postoperatively (P < 0.05), but there was no significant difference during the rest of the postoperative period (1 hour, 1 week, and 1 month). In addition, no significant differences were found in IOP, corneal density, corneal biomechanics, corneal endothelial cells, and corneal morphology. No visual decline or severe postoperative complications were found in the patients in this study.ConclusionsInterlamellar irrigation did not affect IOP, corneal parameters, morphology, complications, or UDVA at 1 hour, 1 week, and 1 month after the operation, but it may promote UDVA 1 day after the operation.Subject terms: Refractive errors, Outcomes research, Surgery 相似文献
45.
46.
正损害控制性剖腹术提出已经近30年,随着负压封闭引流辅助的暂时性腹腔关闭(temporary abdominal closure,TAC)技术的发展和成熟,TAC显著改善了腹腔间隙综合征、严重腹部创伤和腹腔感染等患者的全身血液灌注和脏器功能,降低了病死率~([1-2])。虽然临床高度重视开放腹腔术后的早期腹部切口确定性关闭,但仍然有10%~25%的患者需要植皮形成计划性腹疝(planned ventral hernia,PVH)~([3]),这些患者需要在6~12个月后行确定性腹壁重建,常需应用腹壁分离技术~([4])或生物补片~([5])等人工材料,可能发生肠瘘、切口感染等并发症, 相似文献
47.
Effects of Price,Information, and Transactions Cost Interventions to Raise Voluntary Enrollment in a Social Health Insurance Scheme: A Randomized Experiment in the Philippines
下载免费PDF全文
![点击此处可从《Health economics》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Joseph J. Capuno Aleli D. Kraft Stella Quimbo Carlos R. Tan Jr. Adam Wagstaff 《Health economics》2016,25(6):650-662
A cluster randomized experiment was undertaken testing two sets of interventions encouraging enrollment in the Individually Paying Program (IPP), the voluntary component of the Philippines' social health insurance program. In early 2011, 1037 unenrolled IPP‐eligible families in 179 randomly selected intervention municipalities were given an information kit and offered a 50% premium subsidy valid until the end of 2011; 383 IPP‐eligible families in 64 control municipalities were not. In February 2012, the 787 families in the intervention sites who were still IPP‐eligible but had not enrolled had their vouchers extended, were resent the enrollment kits and received SMS reminders. Half the group also received a ‘handholding’ intervention: in the endline interview, the enumerator offered to help complete the enrollment form, deliver it to the insurer's office in the provincial capital, and mail the membership cards. The main intervention raised the enrollment rate by 3 percentage points (ppts) (p = 0.11), with an 8 ppt larger effect (p < 0.01) among city‐dwellers, consistent with travel time to the insurance office affecting enrollment. The handholding intervention raised enrollment by 29 ppts (p < 0.01), with a smaller effect (p < 0.01) among city‐dwellers, likely because of shorter travel times, and higher education levels facilitating unaided completion of the enrollment form. Copyright © The World Bank Health Economics © 2015 John Wiley & Sons, Ltd. 相似文献
48.
Wen Wang Yanmei Liu Chuan Yu Jing Tan Weiyi Xiong Duo Dong 《Expert opinion on drug safety》2020,19(3):339-347
ABSTRACTObjectives: Limited evidence has suggested that cefoperazone-sulbactam causes coagulation disorders and bleeding.Methods: The authors conducted a retrospective study to compare patients receiving cefoperazone-sulbactam versus those treated with cefoperazone-tazobactam or ceftazidime. Propensity-score matching was used to explore whether treatment with cefoperazone-sulbactam increased the risk of prothrombin time (PT) prolongation, coagulation disorders, and bleeding, or decreased platelets (PLT).Results: The cohort included 23,242 patients. Among patients receiving cefoperazone-sulbactam, the risk of PT prolongation, coagulation disorders, decreased PLT, and bleeding was 5.3%, 9.2%, 15.7%, and 4.2%, respectively. Propensity-score matching analyses suggested that cefoperazone-sulbactam increased the risk of PT prolongation (aOR 2.26, 95% CI 1.61–3.18), coagulation disorders (aOR 1.81, 95% CI 1.43–2.30), and decreased PLT (aOR 1.46, 95% CI 1.25–1.72), but not increase bleeding (aOR 1.05, 95% CI 0.79–1.40) compared with ceftazidime. Patients receiving cefoperazone-sulbactam had higher risk of PT prolongation (aOR 1.53, 95% CI 1.11–2.10), coagulation disorders (aOR 1.53, 95% CI 1.21–1.95), but not decreased PLT (aOR 0.93, 95% CI 0.81–1.07) or bleeding (aOR 1.11, 95% CI 0.87–1.42), compared with those receiving cefoperazone-tazobactam.Conclusion: Cefoperazone-sulbactam may be associated with a higher risk of PT prolongation and coagulation disorders compared with cefoperazone-tazobactam and ceftazidime. 相似文献
49.
50.